Cargando…
Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
Radotinib (Supect™) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI). Other TKIs, including imatinib and nilotinib, were also developed for treatment of CML, and recent studies were increasing about the therapeutic effects of other TKIs on solid tum...
Autores principales: | Kim, Kyung Eun, Park, Sunyoung, Cheon, Soyoung, Kim, Dong Yeon, Cho, Dae Jin, Park, Jeong Min, Hur, Dae Young, Park, Hyun Jeong, Cho, Daeho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330826/ https://www.ncbi.nlm.nih.gov/pubmed/30687767 http://dx.doi.org/10.1155/2018/9580561 |
Ejemplares similares
-
The Effects of Artemisinin on the Cytolytic Activity of Natural Killer (NK) Cells
por: Houh, Youn Kyung, et al.
Publicado: (2017) -
Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease
por: Choi, Yeong-Gon, et al.
Publicado: (2023) -
The Role of Erythroid Differentiation Regulator 1 (ERDR1) in the Control of Proliferation and Photodynamic Therapy (PDT) Response
por: Park, Sunyoung, et al.
Publicado: (2020) -
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
por: Lee, Saebom, et al.
Publicado: (2018) -
Erythroid Differentiation Regulator 1 Ameliorates Collagen-Induced Arthritis via Activation of Regulatory T Cells
por: Kim, Myun Soo, et al.
Publicado: (2020)